1. Home
  2. WLFC vs RCUS Comparison

WLFC vs RCUS Comparison

Compare WLFC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • WLFC
  • RCUS
  • Stock Information
  • Founded
  • WLFC 1985
  • RCUS 2015
  • Country
  • WLFC United States
  • RCUS United States
  • Employees
  • WLFC N/A
  • RCUS N/A
  • Industry
  • WLFC Industrial Specialties
  • RCUS Biotechnology: Pharmaceutical Preparations
  • Sector
  • WLFC Consumer Discretionary
  • RCUS Health Care
  • Exchange
  • WLFC Nasdaq
  • RCUS Nasdaq
  • Market Cap
  • WLFC 983.1M
  • RCUS 906.4M
  • IPO Year
  • WLFC 1996
  • RCUS 2018
  • Fundamental
  • Price
  • WLFC $136.81
  • RCUS $9.15
  • Analyst Decision
  • WLFC
  • RCUS Buy
  • Analyst Count
  • WLFC 0
  • RCUS 9
  • Target Price
  • WLFC N/A
  • RCUS $20.86
  • AVG Volume (30 Days)
  • WLFC 180.4K
  • RCUS 958.9K
  • Earning Date
  • WLFC 08-05-2025
  • RCUS 08-07-2025
  • Dividend Yield
  • WLFC 0.71%
  • RCUS N/A
  • EPS Growth
  • WLFC 66.69
  • RCUS N/A
  • EPS
  • WLFC 14.50
  • RCUS N/A
  • Revenue
  • WLFC $594,146,000.00
  • RCUS $141,000,000.00
  • Revenue This Year
  • WLFC $16.35
  • RCUS N/A
  • Revenue Next Year
  • WLFC $10.53
  • RCUS $28.73
  • P/E Ratio
  • WLFC $9.68
  • RCUS N/A
  • Revenue Growth
  • WLFC 35.29
  • RCUS N/A
  • 52 Week Low
  • WLFC $71.15
  • RCUS $6.50
  • 52 Week High
  • WLFC $235.43
  • RCUS $18.98
  • Technical
  • Relative Strength Index (RSI)
  • WLFC 50.10
  • RCUS 58.09
  • Support Level
  • WLFC $134.70
  • RCUS $9.17
  • Resistance Level
  • WLFC $142.12
  • RCUS $9.97
  • Average True Range (ATR)
  • WLFC 6.35
  • RCUS 0.47
  • MACD
  • WLFC 0.01
  • RCUS 0.14
  • Stochastic Oscillator
  • WLFC 44.63
  • RCUS 77.15

About WLFC Willis Lease Finance Corporation

Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Share on Social Networks: